Meeting
2018 ASCO Annual Meeting
Treatment outcomes for patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) pts and DNA damage repair gene mutations.
Authors
Steven Yip
BC Cancer Agency Vancouver Cancer Centre, Vancouver, BC, Canada
Steven Yip , Arkhjamil Angeles , Arshia Beigi , Evan W Warner , Daniel Khalaf , Katherine Sunderland , Gillian Rae Vandekerkhove , Matti Annala , Kasmintan A Schrader , Alexander William Wyatt , Kim N. Chi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Epidemiology/Outcomes
Citation
J Clin Oncol 36, 2018 (suppl; abstr 5069)
DOI
10.1200/JCO.2018.36.15_suppl.5069
Abstract #
5069
Poster Bd #
296
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Final results of a pilot study of docetaxel and carboplatin for treatment of patients with mCRPC containing biallelic inactivation of genes in the homologous recombination DNA repair pathway.
First Author: Ruben Raychaudhuri
Poster
2020 Genitourinary Cancers Symposium
A pilot study of docetaxel and carboplatin for treatment of patients with mCRPC containing biallelic inactivation of genes in the BRCA1/2 pathway.
First Author: Heather H. Cheng
Poster
2024 ASCO Genitourinary Cancers Symposium
A multicohort phase 2 trial of ADT, docetaxel plus nivolumab in patients with de novo metastatic hormone-sensitive prostate cancer enriched for inflamed tumors and DNA damage repair defects.
First Author: Xiao X. Wei
Poster
2022 ASCO Genitourinary Cancers Symposium
BrUOG360: A phase Ib/II study of copanlisib combined with rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Benedito A. Carneiro